Market Research Logo

Herpes Labialis Treatment Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027

Herpes Labialis Treatment Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027

The global market for herpes labialis treatment is poised to expand at a moderate CAGR of 4.6% over 2017-2027. Up from US$ 869.3 Mn achieved in 2017, the global herpes labialis treatment market will possibly reach beyond US$ 1.3 Bn by the end of 2027.

Soaring penetration of generics and frequent transformations in disease treatment will collectively push the market up, whereas innovations in drug type and mode of action will accelerate the demand for herpes labialis treatment in near future. Apart from increasing prevalence of viral infections and rising R&D investments, mergers and acquisitions among the leading companies will also play a crucial role in uplifting the market performance. Key Players Strongly Support North America’s Dominance

With over 35% value share, North America stood the top market for herpes labialis treatment in 2017. This region is expected to continue its dominance through the forecast period, followed by Western Europe, which recorded over 20% share of the total market value in 2017. APEJ and MEA are also slated for decent market value shares over the assessment period. The North American market is foreseen to take a moderate leap from US$ 310.3 Mn (2017) to US$ 457.1 Mn by the end of forecast period at a CAGR of 3.9%. While the US is expected to maintain dominance, Canada is presumed to witness higher growth during the 10-year period. Increasing efforts and investments in examining clinical efficacy of drugs through research and development, frequent product innovation, and rapid development of cost-effective and advanced treatment options are identified to be the key factors strengthening the growth of North America’s market for herpes labialis treatment.

US-based Companies Lead Market, Extended Product Portfolio Remains Paramount

A majority of US-based leaders in market are concentrating on new product launches through organic and inorganic growth. While strategic collaborations are likely to provide the market with a significant thrust, expansion of existing product portfolio is likely to be the agenda for key players. As FDI policies regulating the pharmaceuticals industry within developing economies are often considered relatively more liberal, established global herpes labialis treatment market players are most likely to amplify their mark within developing regions over the forecast period.

Pfizer Inc., one of the leading players in herpes labialis treatment market, is a New York-based company. With a flagship product - Acyclovir sodium injection, which is a pharmaceutical product used as an antiviral agent, this brand sells in two segments viz. essential health and innovative health. Acquisition of a leader in biosimilar and injectable - Hospira Inc. has helped the company to expand its portfolio in herpes injectable.

Mylan NV, based in Canonsburg, is a leader in Valacyclovir, Acyclovir, and Famciclovir. While the company already has a diversified product portfolio including a vast range of generics and specialty products, it has recently widened its R&D infrastructure post-acquisition of Meda Pharma. Generic drug approvals seem to be a booster for several opportunities in the herpes infection treatment market. In April 2017, Mylan Pharmaceuticals (subsidiary) received US FDA’s final approval for Acyclovir Ointment USP.

Abbott Laboratories is based in Illinois and specializes in Acyclovir Sodium – an injectable antiviral agent. With a broad portfolio serving over 150 countries, the company is currently focusing on expanding its presence in Indian, Chinese, Russian, Colombian, and a few other developing markets. Growing R&D expenditure is foreseen to aid the company in near future. The company divested its branded generics business in developed markets and retained the business in emerging markets in order to capitalize the growing emerging branded generics market.


1. Executive Summary
1.1. Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Herpes Labialis Treatment Market View Point
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. North America Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027
4.1. Introduction
4.2. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
4.2.1. U.S.
4.2.2. Canada
4.3. Market Size (US$ Mn) Forecast By Country, 2017–2027
4.3.1. U.S.
4.3.2. Canada
4.4. Historical Market Size (US$ Mn) and Analysis By Drug Class, 2012–2016
4.4.1. Acyclovir
4.4.2. Valacyclovir
4.4.3. Penciclovir
4.4.4. Famciclovir
4.4.5. Docosanol
4.4.6. Others
4.5. Market Size (US$ Mn) and Forecast By Drug Class, 2017–2027
4.5.1. Acyclovir
4.5.2. Valacyclovir
4.5.3. Penciclovir
4.5.4. Famciclovir
4.5.5. Docosanol
4.5.6. Others
4.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016
4.6.1. Oral
4.6.2. Topical
4.6.3. Combination
4.7. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027
4.7.1. Oral
4.7.2. Topical
4.7.3. Combination
4.8. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
4.8.1. Hospital Pharmacies
4.8.2. Retail Pharmacies
4.8.3. Drug Stores
4.8.4. Online Pharmacies
4.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
4.9.1. Hospital Pharmacies
4.9.2. Retail Pharmacies
4.9.3. Drug Stores
4.9.4. Online Pharmacies
4.10.Market Attractiveness Analysis
4.10.1. By Country
4.10.2. By Drug Class
4.10.3. By Route of Administration
4.10.4. By Distribution Channel
4.11.Key Participants Market Presence (Intensity Map)
5. Latin America Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027
5.1. Introduction
5.2. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
5.2.1. Brazil
5.2.2. Mexico
5.2.3. Rest of Latin America
5.3. Market Size (US$ Mn) Forecast By Country, 2017–2027
5.3.1. Brazil
5.3.2. Mexico
5.3.3. Rest of Latin America
5.4. Historical Market Size (US$ Mn) and Analysis By Drug Class, 2012–2016
5.4.1. Acyclovir
5.4.2. Valacyclovir
5.4.3. Penciclovir
5.4.4. Famciclovir
5.4.5. Docosanol
5.4.6. Others
5.5. Market Size (US$ Mn) and Forecast By Drug Class, 2017–2027
5.5.1. Acyclovir
5.5.2. Valacyclovir
5.5.3. Penciclovir
5.5.4. Famciclovir
5.5.5. Docosanol
5.5.6. Others
5.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016
5.6.1. Oral
5.6.2. Topical
5.6.3. Combination
5.7. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027
5.7.1. Oral
5.7.2. Topical
5.7.3. Combination
5.8. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
5.8.1. Hospital Pharmacies
5.8.2. Retail Pharmacies
5.8.3. Drug Stores
5.8.4. Online Pharmacies
5.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
5.9.1. Hospital Pharmacies
5.9.2. Retail Pharmacies
5.9.3. Drug Stores
5.9.4. Online Pharmacies
5.10.Market Attractiveness Analysis
5.10.1. By Country
5.10.2. By Drug Class
5.10.3. By Route of Administration
5.10.4. By Distribution Channel
5.11.Key Participants Market Presence (Intensity Map)
6. Western Europe Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027
6.1. Introduction
6.2. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
6.2.1. Germany
6.2.2. Italy
6.2.3. France
6.2.4. Spain
6.2.5. U.K.
6.2.6. BENELUX
6.2.7. Nordic
6.2.8. Rest of Western Europe
6.3. Market Size (US$ Mn) Forecast By Country, 2017–2027
6.3.1. Germany
6.3.2. Italy
6.3.3. France
6.3.4. Spain
6.3.5. U.K.
6.3.6. BENELUX
6.3.7. Nordic
6.3.8. Rest of Western Europe
6.4. Historical Market Size (US$ Mn) and Analysis By Drug Class, 2012–2016
6.4.1. Acyclovir
6.4.2. Valacyclovir
6.4.3. Penciclovir
6.4.4. Famciclovir
6.4.5. Docosanol
6.4.6. Others
6.5. Market Size (US$ Mn) and Forecast By Drug Class, 2017–2027
6.5.1. Acyclovir
6.5.2. Valacyclovir
6.5.3. Penciclovir
6.5.4. Famciclovir
6.5.5. Docosanol
6.5.6. Others
6.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016
6.6.1. Oral
6.6.2. Topical
6.6.3. Combination
6.7. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027
6.7.1. Oral
6.7.2. Topical
6.7.3. Combination
6.8. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
6.8.1. Hospital Pharmacies
6.8.2. Retail Pharmacies
6.8.3. Drug Stores
6.8.4. Online Pharmacies
6.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
6.9.1. Hospital Pharmacies
6.9.2. Retail Pharmacies
6.9.3. Drug Stores
6.9.4. Online Pharmacies
6.10.Market Attractiveness Analysis
6.10.1. By Country
6.10.2. By Drug Class
6.10.3. By Route of Administration
6.10.4. By Distribution Channel
6.11.Key Participants Market Presence (Intensity Map)
7. Asia Pacific excluding Japan Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
7.2.1. China
7.2.2. India
7.2.3. Australia and New Zealand
7.2.4. ASEAN
7.2.5. Rest of APEJ
7.3. Market Size (US$ Mn) Forecast By Country, 2017–2027
7.3.1. China
7.3.2. India
7.3.3. Australia and New Zealand
7.3.4. ASEAN
7.3.5. Rest of APEJ
7.4. Historical Market Size (US$ Mn) and Analysis By Drug Class, 2012–2016
7.4.1. Acyclovir
7.4.2. Valacyclovir
7.4.3. Penciclovir
7.4.4. Famciclovir
7.4.5. Docosanol
7.4.6. Others
7.5. Market Size (US$ Mn) and Forecast By Drug Class, 2017–2027
7.5.1. Acyclovir
7.5.2. Valacyclovir
7.5.3. Penciclovir
7.5.4. Famciclovir
7.5.5. Docosanol
7.5.6. Others
7.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016
7.6.1. Oral
7.6.2. Topical
7.6.3. Combination
7.7. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027
7.7.1. Oral
7.7.2. Topical
7.7.3. Combination
7.8. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
7.8.1. Hospital Pharmacies
7.8.2. Retail Pharmacies
7.8.3. Drug Stores
7.8.4. Online Pharmacies
7.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
7.9.1. Hospital Pharmacies
7.9.2. Retail Pharmacies
7.9.3. Drug Stores
7.9.4. Online Pharmacies
7.10.Market Attractiveness Analysis
7.10.1. By Country
7.10.2. By Drug Class
7.10.3. By Route of Administration
7.10.4. By Distribution Channel
7.11.Key Participants Market Presence (Intensity Map)
8. Japan Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027
8.1. Introduction
8.2. Historical Market Size (US$ Mn) and Analysis By Drug Class, 2012–2016
8.2.1. Acyclovir
8.2.2. Valacyclovir
8.2.3. Penciclovir
8.2.4. Famciclovir
8.2.5. Docosanol
8.2.6. Others
8.3. Market Size (US$ Mn) and Forecast By Drug Class, 2017–2027
8.3.1. Acyclovir
8.3.2. Valacyclovir
8.3.3. Penciclovir
8.3.4. Famciclovir
8.3.5. Docosanol
8.3.6. Others
8.4. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016
8.4.1. Oral
8.4.2. Topical
8.4.3. Combination
8.5. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027
8.5.1. Oral
8.5.2. Topical
8.5.3. Combination
8.6. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
8.6.1. Hospital Pharmacies
8.6.2. Retail Pharmacies
8.6.3. Drug Stores
8.6.4. Online Pharmacies
8.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
8.7.1. Hospital Pharmacies
8.7.2. Retail Pharmacies
8.7.3. Drug Stores
8.7.4. Online Pharmacies
8.8. Market Attractiveness Analysis
8.8.1. By Country
8.8.2. By Drug Class
8.8.3. By Route of Administration
8.8.4. By Distribution Channel
8.9. Key Participants Market Presence (Intensity Map)
9. Middle East & Africa Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
9.2.1. GCC Countries
9.2.2. South Africa
9.2.3. Rest of MEA
9.3. Market Size (US$ Mn) Forecast By Country, 2017–2027
9.3.1. GCC Countries
9.3.2. South Africa
9.3.3. Rest of MEA
9.4. Historical Market Size (US$ Mn) and Analysis By Drug Class, 2012–2016
9.4.1. Acyclovir
9.4.2. Valacyclovir
9.4.3. Penciclovir
9.4.4. Famciclovir
9.4.5. Docosanol
9.4.6. Others
9.5. Market Size (US$ Mn) and Forecast By Drug Class, 2017–2027
9.5.1. Acyclovir
9.5.2. Valacyclovir
9.5.3. Penciclovir
9.5.4. Famciclovir
9.5.5. Docosanol
9.5.6. Others
9.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016
9.6.1. Oral
9.6.2. Topical
9.6.3. Combination
9.7. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027
9.7.1. Oral
9.7.2. Topical
9.7.3. Combination
9.8. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
9.8.1. Hospital Pharmacies
9.8.2. Retail Pharmacies
9.8.3. Drug Stores
9.8.4. Online Pharmacies
9.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
9.9.1. Hospital Pharmacies
9.9.2. Retail Pharmacies
9.9.3. Drug Stores
9.9.4. Online Pharmacies
9.10.Market Attractiveness Analysis
9.10.1. By Country
9.10.2. By Drug Class
9.10.3. By Route of Administration
9.10.4. By Distribution Channel
9.11.Key Participants Market Presence (Intensity Map)
10. Forecast Factors: Relevance and Impact
11. Forecast Assumptions
12. Competition Landscape
12.1.Competition Dashboard
12.2.Company Profiles (Details – Overview, Financials, Strategy, SWOT, Recent Developments)
12.2.1. Teva Pharmaceuticals, Inc.
12.2.2. Abbott Laboratories
12.2.3. Sun Pharmaceuticals Industries Ltd.
12.2.4. Mylan N.V.
12.2.5. Pfizer Inc.
12.2.6. GlaxoSmithKline plc.
12.2.7. Dr. Reddy’s Laboratories, ltd.
12.2.8. Novartis AG
12.2.9. Valeant Pharmaceuticals International Inc.
13. Global Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027, By Region
13.1.Introduction/Key Findings
13.2.Historical Market Size (US$ Mn) Trend Analysis By Region, 2012–2016
13.2.1. North America
13.2.2. Latin America
13.2.3. Western Europe
13.2.4. Eastern Europe
13.2.5. Asia Pacific excluding Japan
13.2.6. Japan
13.2.7. Middle East & Africa
13.3.Market Size (US$ Mn) Forecast By Region, 2017–2027
13.3.1. North America
13.3.2. Latin America
13.3.3. Western Europe
13.3.4. Eastern Europe
13.3.5. Asia Pacific excluding Japan
13.3.6. Japan
13.3.7. Middle East & Africa
13.4.Market Attractiveness Analysis By Region
14. Global Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027, By Drug Class
14.1.Introduction/Key Findings
14.2.Historical Market Size (US$ Mn) and Analysis By Drug Class, 2012–2016
14.2.1. Acyclovir
14.2.2. Valacyclovir
14.2.3. Penciclovir
14.2.4. Famciclovir
14.2.5. Docosanol
14.2.6. Others
14.3.Market Size (US$ Mn) and Forecast By Drug Class, 2017–2027
14.3.1. Acyclovir
14.3.2. Valacyclovir
14.3.3. Penciclovir
14.3.4. Famciclovir
14.3.5. Docosanol
14.3.6. Others
14.4.Market Attractiveness Analysis By Drug Class
15. Global Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027, By Route of Administration
15.1.Introduction/Key Findings
15.2.Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016
15.2.1. Oral
15.2.2. Topical
15.2.3. Combination
15.3.Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027
15.3.1. Oral
15.3.2. Topical
15.3.3. Combination
15.4.Market Attractiveness Analysis By Route of Administration
16. Global Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027, By Distribution Channel
16.1.Introduction/Key Findings
16.2.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2012–2016
16.2.1. Hospital Pharmacies
16.2.2. Retail Pharmacies
16.2.3. Drug Stores
16.2.4. Online Pharmacies
16.3.Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2027
16.3.1. Hospital Pharmacies
16.3.2. Retail Pharmacies
16.3.3. Drug Stores
16.3.4. Online Pharmacies
16.4.Market Attractiveness Analysis By Distribution Channel
17. Global Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027
17.1.Market Size and Y-o-Y Growth
17.2.Absolute $ Opportunity
17.3.Market Value Chain

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report